(Q38586044)

4 September 2017

title

Biosimilar monoclonal antibodies: the scientific basis for extrapolation (English)

1 reference

4 September 2017

1 reference

Huub Schellekens

1

1 reference

4 September 2017

Erika Lietzan

series ordinal

2

1 reference

4 September 2017

Freddy Faccin

series ordinal

3

1 reference

4 September 2017

Jaap Venema

series ordinal

4

1 reference

4 September 2017

language of work or name

English

0 references

publication date

12 September 2015

1 reference

Expert Opinion on Biological Therapy

4 September 2017

published in

1 reference

4 September 2017

volume

15

1 reference

4 September 2017

issue

11

1 reference

4 September 2017

page(s)

1633-1646

1 reference

Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars?

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1083552

The role of biosimilars in the treatment of rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1083552

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1083552

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1083552

Comparability and biosimilarity: considerations for the healthcare provider

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1083552

Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1083552

The challenge of indication extrapolation for infliximab biosimilars

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1083552

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1083552

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1083552

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1083552

Mechanisms of action of anti-tumor necrosis factor α agents in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1083552

Biologics: an update and challenge of their pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1083552

Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1083552

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1083552

Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1083552

Dealing with immunogenicity of biologicals: assessment and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1083552

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1083552

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1083552

Infliximab for the treatment of fistulas in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1083552

Infliximab maintenance therapy for fistulizing Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1083552

Infliximab for induction and maintenance therapy for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1083552

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1083552

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1083552

Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1083552

A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1083552

Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1083552

10.1517/14712598.2015.1083552

21 January 2018

Identifiers

DOI

1 reference

4 September 2017

1 reference